

Pharmaceutical Pipeline – Key Events in 2019*

Potential Approvals US/EU

| | |
|------------------------------------|---|
| ERLEADA™ (apalutamide) | – Non-metastatic prostate cancer (EU) ✓ – Metastatic castrate sensitive prostate cancer (TITAN) (US) |
| BALVERSA™ (erdafitinib) | – Urothelial cancer (US) ✓ |
| SPRAVATO™ (esketamine nasal spray) | – Treatment-resistant depression (US ✓ / EU) |
| STELARA® | – Ulcerative Colitis (US / EU) |
| XARELTO® | – VTE prevention medically ill patients (US) |
| IMBRUVICA® | – Frontline CLL combo w/obinutuzumab (US ✓ / EU) – Waldenström's Macroglobulinemia in combo w/rituximab (EU) |
| TREMFYA® | – Psoriasis Patient-Controlled Injector (US) ✓ |
| DARZALEX® | – Frontline Multiple Myeloma transplant ineligible in combo w/ lenalidomide and low dose dexamethasone (MAIA) (US) ✓ – Frontline Multiple Myeloma transplant (CASSIOPEIA) (US) |
| INVOKANA® | – Treatment of CKD in patients with T2DM (US) |
| rilpivrine long acting maintenance | – HIV (US) |

Planned Submissions US/EU

| | |
|------------------------------------|--|
| rilpivrine long acting maintenance | – HIV (US ✓ / EU) |
| SPRAVATO™ (esketamine nasal spray) | – Major Depressive Disorder at Imminent Risk for Suicide (US) |
| DARZALEX® | – Frontline Multiple Myeloma transplant ineligible in combo w/ lenalidomide and low dose dexamethasone (MAIA) (US / EU) ✓ – Frontline Multiple Myeloma transplant (CASSIOPEIA) (US / EU) ✓ – Subcutaneous Formulation in patients with relapsed or refractory multiple myeloma (COLUMBA) (US ✓ / EU) |
| ERLEADA™ (apalutamide) | – Metastatic castrate sensitive prostate cancer (TITAN) (US / EU) ✓ |
| INVOKANA® | – Treatment of CKD in patients with T2DM (US ✓ / EU) |
| TREMFYA® | – Psoriatic Arthritis (US / EU) |

✓ = Achieved

Potential Clinical Data Presentations

Phase 3

| | |
|-------------------------------------|---|
| INVOKANA® | – Treatment of CKD in patients with T2DM (CREDESCENCE) ✓ |
| STELARA® | – Ulcerative Colitis (UNIFI) ✓ |
| Rilpivirine long Acting Maintenance | – HIV (ATLAS / FLAIR) ✓ |
| TREMFYA® | – Psoriatic Arthritis (DISCOVER 1 & 2) |
| ERLEADA™ (apalutamide) | – Metastatic castrate sensitive prostate cancer (TITAN) ✓ |
| SPRAVATO™ (esketamine) | – Major Depressive Disorder at Imminent Risk for Suicide (ASPIRE I, ASPIRE II) |
| DARZALEX® | – Subcutaneous Formulation in patients with relapsed or refractory multiple myeloma (COLUMBA) ✓ – Frontline Multiple Myeloma transplant (CASSIOPEIA) ✓ |
| UPTRAVI® | – Pulmonary arterial hypertension IV (AC-065A309) ✓ – Pulmonary arterial hypertension (GRIPHON) ✓ |

Potential Clinical Data Presentations

Phase 2

| | |
|-------------|--|
| DARZALEX® | – Subcutaneous formulation in combination with standard multiple myeloma treatments (PLEIADES) |
| HIV Vaccine | – HIV (ASCENT) |
| Niraparib | – L3 Metastatic Castration-Resistant Prostate Cancer (GALAHAD) ✓ |